

Document and Entity Information	9 Months Ended	
	Jun. 30, 2013	May 10, 2013
Document and Entity Information [Abstract]		
Entity Registrant Name	MEDICAL INTERNATIONAL TECHNOLOGY INC	
Entity Central Index Key	0001112372	
Amendment Flag	false	
Current Fiscal Year End Date	--09-30	
Document Type	10-Q	
Document Period End Date	Jun. 30, 2013	
Document Fiscal Year Focus	2013	
Document Fiscal Period Focus	Q3	
Entity Filer Category	Smaller Reporting Company	
Entity Common Stock, Shares Outstanding		83,804,627

Consolidated Balance Sheet (USD \$)	Jun. 30, 2013	Sep. 30, 2012
Current Assets		
Cash and cash equivalents	\$ 7,981	\$ 303,497
Accounts receivable	36,987	56,067
Inventories	306,947	316,440
Prepaid expenses	8,826	20,203
Total Current Assets	360,651	696,207
Long Term Investment		
Investment in MT China Joint Venture	2,278	146,343
Property and Equipment		
Tooling and machinery	667,930	713,779
Furniture and office equipment	136,303	144,775
Leasehold improvements	27,871	29,785
Total property and equipment	832,104	888,339
Less accumulated depreciation	(657,973)	(612,592)
Total property and equipment, net	174,131	275,747
Other Assets		
Patents (net of accumulated amortization of \$10,149 and \$13,516)	36,249	44,857
Total assets	573,309	1,163,154
Current Liabilities		
Bank line	9,513	101,660
Deferred income	1,276,427	1,385,906
Accounts payable and accrued expenses	166,073	160,174
Current portion of long term debts	51,442	51,442
Total current liabilities	1,503,455	1,699,182
Long-Term Debts	101,310	148,536
Total Liabilities	1,604,765	1,847,718
Stockholders' Equity (Deficit)		
Preferred stock, \$.0001 par value; 3,000,000 shares authorized; No issued and outstanding shares.		
Common stock, \$.0001 par value; 100,000,000 shares authorized; 83,804,627 and 79,090,627 issued and outstanding, respectively	7,979	7,979
Additional paid-in capital	12,867,476	12,867,476
Deficit	(13,505,949)	(13,172,164)
Other comprehensive income (loss)	(399,962)	(387,855)
Total Stockholders' Equity (Deficit)	(1,030,456)	(684,564)
Total Liabilities and Stockholders' Equity (Deficit)	\$ 573,309	\$ 1,163,154

Consolidated Balance Sheet (Parenthetical) (USD \$)	Jun. 30, 2013	Sep. 30, 2012
Balance Sheet [Abstract]		
Accumulated amortization (Patents)	\$ 10,149	\$ 13,516
Preferred stock, par value	\$ 0.0001	\$ 0.0001
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued		
Preferred stock, shares outstanding		
Common stock, par value	\$ 0.0001	\$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	83,804,627	79,090,627
Common stock, shares outstanding	83,804,627	79,090,627

Consolidated Statements of Operations (Unaudited) (USD \$)	3 Months Ended		9 Months Ended	
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Statements of Operations [Abstract]				

Sales	\$ 238,158	\$ 401,157	\$ 528,310	\$ 828,644
Cost of sales	(97,307)	(95,989)	(166,897)	(195,486)
Gross profit (loss)	140,851	305,168	361,413	633,158
Operating expenses				
Selling, general, and administrative expenses	(336,492)	(215,403)	(540,372)	(664,266)
Total operating expenses	(336,492)	(215,403)	(540,372)	(664,266)
Loss from operations	(195,641)	89,765	(178,959)	(31,108)
Other Income (Expense) Equity earnings (loss) on MIT China Joint Venture	(90,445)	(80,166)	(144,065)	(184,773)
Interest income/loss	539	240	760	824
Interest expense	(5,997)	(4,065)	(11,521)	(39,089)
Other income (expense), net	(95,903)	(83,991)	(154,826)	(223,038)
Net Loss	\$ (291,544)	\$ 5,774	\$ (333,785)	\$ (254,146)
Basic (loss) per share	\$ (0.003)	\$ (0.0001)	\$ (0.004)	\$ (0.003)
Basic w eighted average shares outstanding	83,804,627	83,804,627	83,804,627	83,804,627

Consolidated Statements of Cash Flows (USD \$)	9 Months Ended	
	Jun. 30, 2013	Jun. 30, 2012
Cash flows from operating activities:		
Net loss	\$ (333,785)	\$ (254,146)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:		
Equity loss from MIT China Joint Venture	(144,065)	(184,773)
Depreciation and amortization expense	94,880	94,517
Common stock issued for services		
Related party payables settle by common stock		
Capitalization of related party debts		
Changes in:		
Accounts receivable	19,080	(3,340)
Inventories	9,493	46,082
Prepaid expenses	11,377	11,380
Accounts payable and accrued liabilities	5,900	61,700
Deferred income	(109,479)	518
Net cash used by operating activities	(158,469)	141,484
Cash flows from investing activities:		
Acquisition of patents	(5,251)	(16,692)
Investment in MIT China joint venture		
Tooling and machinery		(47,718)
Net cash used by investing activities	(5,251)	(64,410)
Cash flows from financing activities:		
Bank line	(92,147)	(30,765)
Bank loans	(48,226)	27,953
Proceeds from issuance of stock, net		63,340
Increase in amounts due to related parties		(152,723)
Issuance of notes payable		
Repayment on notes payable		
Net cash provided from financing activities	(132,367)	(92,195)
Effect of exchange rates	8,487	4,232
Increase (decrease) in cash	(295,606)	(10,889)
Cash, beginning of period	303,497	10,889
Cash, end of period	7,981	
Supplemental disclosure of cash flow information:		
Cash paid for interest	10,762	39,089
Cash paid for federal income taxes		
Supplemental disclosure of non-cash transactions		
Common stock issued for debt reductions		

Consolidated Statements of Comprehensive Loss (USD \$)	9 Months Ended	
	Jun. 30, 2013	Jun. 30, 2012
Statements of Comprehensive Loss [Abstract]		
Net loss	\$ (333,785)	\$ (254,146)
Other comprehensive income (loss)		
Foreign currency translation adjustment	(12,106)	(16,742)
Net comprehensive income (loss)	\$ (345,891)	\$ (270,888)

Consolidated Statement of	Total	Common Stock	Additional Paid-In Capital	Deficit
---------------------------	-------	--------------	----------------------------	---------

Stockholders' (Deficit) (USD \$)				
Beginning Balance at Sep. 30, 2012	\$ (684,564)	\$ 7,979	\$ 12,867,386	\$ (13,172,164)
Beginning Balance, Shares at Sep. 30, 2012		83,804,627		
Shares issued for debts				
Shares issued for debts, Shares				
Shares issued for services				
Shares issued for services, Shares				
Shares issued for additional capital				
Shares issued for additional capital, Shares				
Net loss	(333,785)			(333,785)
Balance at Jun. 30, 2013	\$ (1,030,456)	\$ 7,979	\$ 12,867,386	\$ (13,505,949)
Balance, Shares at Jun. 30, 2013		83,894,627		

Basis of Presentation	9 Months Ended	
	Jun. 30, 2013	
Basis of Presentation [Abstract]		
Basis of Presentation	Note 1 – Basis of Presentation	
	Interim Financial Statements	
	<p>The accompanying unaudited condensed consolidated financial statements of Medical International Technology, Inc. ("MIT" or the "Company") and its subsidiary (collectively referred to as the "Company") have been prepared in accordance with accounting principles generally accepted in the United States of America, pursuant to the rules and regulations of the Securities and Exchange Commission. All significant intercompany balances and transactions have been eliminated. These financial statements do not include all information and notes required by accounting principles generally accepted in the United States of America for complete financial statements. It is recommended that these interim unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2012.</p> <p>In the opinion of management, all adjustments (consisting only of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months period ended June 30, 2013 are not necessarily indicative of the results which may be expected for any other interim periods or for the year ending September 30, 2013. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</p>	

Inventories	9 Months Ended	
	Jun. 30, 2013	
Inventories [Abstract]		
Inventories	Note 2 – Inventories	
	Inventories at June 30, 2013 and September 30, 2012 consist of the following:	
		September
	June 30,	30,
	2013	2012
	Raw materials	\$ 211,833 \$ 242,528
	Work in process	83,367 63,255
	Finished goods	11,747 10,657
	Total	<u>\$ 306,947</u> <u>\$ 316,440</u>

Property and Equipment	9 Months Ended	
	Jun. 30, 2013	
Property and Equipment [Abstract]		
Property and Equipment	Note 3 – Property and Equipment	
	<p>The cost of property and equipment is depreciated over the estimated useful lives of the related assets, which range from 5 to 7 years. Depreciation is computed on the straight-line method for financial reporting purposes and on the declining balance method for income tax reporting purposes. Depreciation expense for the nine months ended June 30, 2013 and 2012 was \$84,730 and \$59,370, respectively</p>	

Intangible Assets	9 Months Ended	
	Jun. 30, 2013	
Intangible Assets [Abstract]		
Intangible Assets	Note 4 – Intangible Assets	
	<p>As of June 30, 2013 the Company has net patents on certain technologies aggregating \$36,249. Amortization expense for the years ended June 30, 2013 and 2012 were \$10,149 and \$16,096, respectively. During the nine months ended June 30, 2013, the Company capitalized patent costs on its needle-free injector of \$4,424. Following is a detail of patents at June 30, 2013.</p>	
	Gross Intangible Assets	Accumulated Amortization
	Net Intangible Assets	Weighted Average Life (Years)
	Patents	\$ 67,666 \$ 31,417 \$ 36,249 7.5 through 15

Joint Venture Agreement	9 Months Ended	
	Jun. 30, 2013	
Joint venture agreement [Abstract]		
Joint Venture Agreement	Note 5 – Joint venture agreement	

On May 6, 2009, the Company entered into a certain joint venture agreement (the "Joint Venture Agreement") with Jiangsu Hualan Biotechnology Ltd. (China) ("Jiangsu Hualan"). Pursuant to the Joint Venture Agreement, the parties thereto established a joint venture company, Jiangsu Hualan MIT Medical Technology (MIT China) Ltd. ("MIT China" or the "Joint Venture"), focusing on research, production and sales of medical equipments, import and export of medical equipments and components products, especially Needle-Free Jet Injector products. The total investment by the Joint Venture shall amount to \$2,000,000, and the registered capital shall amount to \$1,400,000. The Company invested cash of \$426,678 and transferred the license rights to produce and sell the Company's needle-free injectors products into the Joint Venture. The license rights were valued at \$280,000 under the agreement. The contributions by the Company resulted in the Company owning 49% of the registered capital of the Joint Venture. Jiangsu Hualan contributed cash of \$714,000, and owns 51% of the registered capital.

Under the Joint Venture Agreement, the Company appointed 1 member, and Jiangsu Hualan appointed 2 members, to the board of directors of the Joint Venture. Profits of the Joint Venture will be allocated based upon each party's investment in the registered capital.

During the period from May 6, 2009 to September 30, 2009, the Joint Venture had not commenced operations. The Joint Venture commenced operations during the Company's 1st quarter of fiscal 2010.

During the third quarter of fiscal year 2011, MIT China purchased 151,000 sq. ft. of land and began construction of its first building in Taizhou (China Medical City). This first building of 40,000 sq. ft. will be used for the production of injectors for the Chinese market. The first stage (the offices) was completed and employees were moved into the facility in August 2012. The second part of the construction is scheduled to be complete during the first quarter of 2013, which will contain the production facility capable of supplying a large number of injectors and disposables to the Chinese market.

In March 2012, MIT China agreed and sold 9% of the joint venture for an investment of 18,000,000 RMB (US\$3,000,000). Jiangsu Hualan now has 46.41%, the Company has 44.59%, and Taizhou Amazon Investment Center has 9% ownership in the MIT China joint venture.

The Company accounts for its investment in MIT China in accordance with Financial Accounting Standards Board Accounting Standards Codification 323, "Investment — Equity Method and Joint Venture" (ASC 323), previously referred to as Accounting Principles Board Opinion No. 18, "The Equity Method of Accounting for Investments in Common Stock." Accordingly, the Company adjusts the carrying amount of its investment in MIT China to recognize its share of earnings or losses. As of September 30, 2012, the Company's recorded investment in the MIT China was \$146,343. During the nine months ended June 30, 2013, the Company recorded an equity loss from its investment in MIT China of \$144,065.

Bank Line	9 Months Ended Jun. 30, 2013
Bank Line [Abstract]	
Bank Line	Note 6 – Bank Line
	The Company has an equipment line of credit up to a maximum of \$350,000. The line is secured by account receivables, inventories, equipment and all other assets of the Company. At June 30, 2013, the Company had \$9,513 outstanding under the agreement.

Related Party Transactions	9 Months Ended Jun. 30, 2013
Related Party Transactions [Abstract]	
Related Party Transactions	Note 7 – Related Party Transactions
	There are not related party balances at June 30, 2013 and September 30, 2012.

Stockholders' Equity (Deficit)	9 Months Ended Jun. 30, 2013
Stockholders' Equity (Deficit) [Abstract]	
Stockholders' Equity (Deficit)	Note 8 – Stockholders' Equity (Deficit)
	Issuance of Common Stock
	From time to time, the Company will issue common stock for services rendered, debt reductions or as part of private placement offerings.
	For the quarter ended June 30, 2013, there was no common stock issuance.
	Preferred Stock
	As of June 30, 2013, there was no preferred stock outstanding. Dividend features and voting rights are at the discretion of the Board of Directors without the requirement of shareholder approval.
	Outstanding Options
	As of June 30, 2013 and 2012, there are no options outstanding to purchase shares of the Company's common stock.
	Outstanding Warrants
	There are no outstanding warrants

Operating Leases	9 Months Ended Jun. 30, 2013	
Operating Leases [Abstract]		
Operating Leases	Note 9 – Operating Leases	
	The Company leases its office and warehouse space under an operating lease that expires on December 31, 2014 that calls for a monthly rent of \$4,300. Rent expense for the year ended June 30, 2013 was approximately \$37,800.	
	Future minimum lease commitments pertaining to the lease expire as follow:	
	Year ended	
	June 30, 2014	51,600
	Dec 31, 2014	25,200
		<u>\$ 76,800</u>

Deferred Income	9 Months Ended	
	Jun. 30, 2013	
Deferred Income [Abstract]		
Deferred Income	Note 10 – Deferred Income	
	Deferred income consists of the following at June 30, 2013 and September 30, 2012:	
	June 30, 2013	September 30, 2012
Deposits from customers and distributors	\$ 203,927	\$ 313,406
Non-refundable Distribution Rights Deposit	1,072,500	1,072,500
Total	\$ 1,276,427	\$ 1,385,906
<p>On November 1, 2007, the Company received a deposit of \$1,300,000 for the worldwide rights to market and sell while maintaining MIT CANADA right to sell all Medical International Technology Inc.'s Needle-Free Jet-Injectors for the human and animal markets. This deposit was part of an agreement under negotiation, which was finalized in January 2009. Upon finalization, the Company began recognizing the deposit into income over the contractual life of the agreement. During the year ended September 30, 2010, the Company recognized \$130,000 into income under this agreement. During 2011, the Company was notified of potential litigation related to this contract. Accordingly, due to the uncertainty in a final resolution, the Company ceased recognizing income related to this contract during 2011. Upon a final resolution of the dispute, the Company will begin amortizing the deposit into income over the remaining contractual life of the agreement.</p>		

Notes Payable	9 Months Ended	
	Jun. 30, 2013	
Notes Payable [Abstract]		
Notes Payable	Note 11 – Notes Payable	
	Long-term debt consists of the following at June 30, 2013 and September 30, 2012:	
	June 30, 2013	September 30, 2012
Note payable to a bank, bearing interest at prime plus 3%, repayment of the loan in sixty (60) equal and consecutive installments of 2,413.12 starting January 20, 2012, secured by equipment, due January 20, 2016.	\$ 94,272	\$ 123,197
Loan Canada Economic Development, no interest, repayment of the contribution in sixteen (16) equal and consecutive quarterly installment starting twelve (12) month after the project completion date.	57,480	76,782
Long-term debt	\$ 151,752	\$ 199,979
<p>Future scheduled principal payments under note agreements are as follows:</p>		
Year ended		
June 30, 2014		51,442
June 30, 2015		51,442
June 30, 2016		48,868
		\$ 151,752

Contingencies	9 Months Ended	
	Jun. 30, 2013	
Contingencies [Abstract]		
Contingencies	Note 12 – Contingencies	
	Legal Proceedings	
<p>We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries' officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.</p>		

Inventories (Tables)	9 Months Ended	
	Jun. 30, 2013	
Inventories [Abstract]		
Components of inventory	June 30, 2013	September 30, 2012
Raw materials	\$211,833	\$ 242,528
Work in process	83,367	63,255
Finished goods	11,747	10,657
Total	\$306,947	\$ 316,440

Intangible Assets (Tables)	9 Months Ended			
	Jun. 30, 2013			
Intangible Assets [Abstract]				
Summary of patents	Gross Intangible Assets	Accumulated Amortization	Net Intangible Assets	Weighted Average Life (Years)
				7.5 through

Patents	\$ 67,666	\$ 31,417	\$ 36,249	15
---------	-----------	-----------	-----------	----

Operating Leases (Tables)	9 Months Ended	
	Jun. 30, 2013	
Operating Leases [Abstract]		
Future minimum lease commitments	Year ended	
	June 30, 2014	51,600
	Dec 31, 2014	25,200
		<u>\$76,800</u>

Deferred Income (Tables)	9 Months Ended	
	Jun. 30, 2013	
Deferred Income [Abstract]		
Components of deferred income	June 30, 2013	September 30, 2012
Deposits from customers and distributors	\$ 203,927	\$ 313,406
Non-refundable Distribution Rights Deposit	1,072,500	1,072,500
Total	<u>\$1,276,427</u>	<u>\$ 1,385,906</u>

Notes Payable (Tables)	9 Months Ended	
	Jun. 30, 2013	
Notes Payable [Abstract]		
Schedule of long-term debt	June 30, 2013	September 30, 2012
Note payable to a bank, bearing interest at prime plus 3%, repayment of the loan in sixty (60) equal and consecutive installments of 2,413.12 starting January 20, 2012, secured by equipment, due January 20, 2016.	\$ 94,272	\$ 123,197
Loan Canada Economic Development, no interest, repayment of the contribution in sixteen (16) equal and consecutive quarterly installment starting twelve (12) month after the project completion date.	57,480	76,782
Long-term debt	<u>\$ 151,752</u>	<u>\$ 199,979</u>
Future scheduled principal payments of long-term debt	Year ended	
	June 30, 2014	51,442
	June 30, 2015	51,442
	June 30, 2016	48,868
		<u>\$ 151,752</u>

Inventories (Details) (USD \$)	Jun. 30, 2013	Sep. 30, 2012
Components of inventory		
Raw materials	\$ 211,833	\$ 242,528
Work in process	83,367	63,255
Finished goods	11,747	10,657
Total	<u>\$ 306,947</u>	<u>\$ 316,440</u>

Property and Equipment (Details) (USD \$)	9 Months Ended	
	Jun. 30, 2013	Jun. 30, 2012
Property and Equipment (Textual)		
Depreciation expense	\$ 84,730	\$ 59,370
Minimum [Member]		
Property and Equipment (Textual)		
Estimated useful lives of property and equipment	5 years	
Maximum [Member]		
Property and Equipment (Textual)		
Estimated useful lives of property and equipment	7 years	

Intangible Assets (Details) (USD \$)	9 Months Ended				
	Jun. 30, 2013	Sep. 30, 2012	Jun. 30, 2013 Patents [Member]	Jun. 30, 2013 Minimum [Member] Patents [Member]	Jun. 30, 2013 Maximum [Member] Patents [Member]
Summary of patents					
Gross Intangible Assets			\$ 67,666		
Accumulated Amortization	10,149	13,516	31,417		
Net Intangible Assets	\$ 36,249	\$ 44,857	\$ 36,249		
Weighted Average Life (Years)				7 years 6 months	15 years

Intangible Assets (Details Textual) (USD \$)	9 Months Ended		
	Jun. 30, 2013	Jun. 30, 2012	Sep. 30, 2012
Intangible Assets (Textual)			
Aggregate net patents	\$ 36,249		\$ 44,857
Amortization expenses	10,149	16,096	

Capitalized patent costs on needle-free injector	\$ 4,424
--	----------

Joint Venture Agreement (Details)	0 Months Ended	1 Months Ended		3 Months Ended		9 Months Ended			0 Months Ended	0 Months Ended	0 Months Ended	
	May 06, 2009 USD (\$) Members	Mar. 31, 2012 USD (\$)	Mar. 31, 2012 CNY	Jun. 30, 2013 USD (\$)	Jun. 30, 2012 USD (\$)	Jun. 30, 2013 USD (\$)	Jun. 30, 2012 USD (\$)	Jun. 30, 2011 sqft				Sep. 30, 2012 USD (\$)
Joint Venture Agreement (Textual)												
Ownership percentage	49.00%	44.59%	44.59%							51.00%	46.41%	9.00%
Cash invested in joint venture		\$ 3,000,000	18,000,000	\$ 2,278		\$ 2,278			\$ 146,343	\$ 714,000		
Number of members appointed under joint venture agreement	1										2	
Total investment to be made by joint venture	2,000,000											
Registered capital	1,400,000											
Investment in joint venture	426,678											
Value of license rights	280,000											
Area of land purchase for construction								151,000				
Area of land use for production of injectors								40,000				
Sale of joint venture percentage for an investment by parent company		9.00%	9.00%									
Equity loss from MIT China Joint Venture					\$ (90,445)	\$ (80,166)	\$ (144,065)	\$ (184,773)				

Bank Line (Details) (USD \$)	Jun. 30, 2013
Bank Line (Textual)	
Maximum equipment line of credit	\$ 350,000
Amount outstanding	\$ 9,513

Operating Leases (Details) (USD \$)	Jun. 30, 2013
Future minimum lease commitments	
June 30, 2014	\$ 51,600
Dec 31, 2014	25,200
Total operating leases	\$ 76,800

Operating Leases (Details Textual) (USD \$)	9 Months Ended Jun. 30, 2013
Operating Leases (Textual)	
Expiry date of operating lease	Dec. 31, 2014
Monthly rent for office and warehouse space	\$ 4,300
Rent expense	\$ 37,800

Deferred Income (Details) (USD \$)	Jun. 30, 2013	Sep. 30, 2012
Components of deferred income		
Deposits from customers and distributors	\$ 203,927	\$ 313,406
Non-refundable Distribution Rights Deposit	1,072,500	1,072,500
Total	\$ 1,276,427	\$ 1,385,906

Deferred Income (Details Textual) (USD \$)	12 Months Ended	
	Sep. 30, 2010	Nov. 01, 2007
Deferred Income (Textual)		
Deposit received for the worldwide rights to market and sell rights		\$ 1,300,000
Deferred revenue recognized	\$ 130,000	

Notes Payable (Details) (USD \$)	Jun. 30, 2013	Sep. 30, 2012
Schedule of long-term debt		
Note payable to a bank, bearing interest at prime plus 3%, repayment of the loan in sixty (60) equal and consecutive installments of 2,413.12 starting January 20, 2012, secured by equipment, due January 20, 2016.	\$ 94,272	\$ 123,197
Loan Canada Economic Development, no interest, repayment of the contribution in sixteen (16) equal and consecutive quarterly installment starting twelve (12) month after the project completion date.	57,480	76,782
Long-term debt	\$ 151,752	\$ 199,979

Notes Payable (Details 1) (USD \$)	Jun. 30, 2013	Sep. 30, 2012
Future scheduled principal payments of long-term debt		
June 30, 2014	\$ 51,442	
June 30, 2015	51,442	
June 30, 2016	48,868	
Long-term debt	\$ 151,752	\$ 199,979

Notes Payable (Details Textual) (USD \$)	9 Months Ended	
	Jun. 30, 2013 Installments	
Notes payable to bank [Member]		
Notes Payable (Textual)		
Interest rate in addition to prime rate	3.00%	
Number of consecutive installments for repayment of long-term debt	60	
Amount of each installment	\$ 2,413.12	
Debt maturity date	Jan. 20, 2016	
Canada economic development [Member]		
Notes Payable (Textual)		
Number of consecutive installments for repayment of long-term debt	16	
Due date of first installment	Twelve (12) month after the project completion date.	